Fluoxetine thermal analytical studies: Fluoxetine ((±)-N-methyl-3-phenyl-3-[(±,±,±-trifluoro-Á-tolyl)-oxy]propylamine hydrochloride is an antidepressant selective serotonin reuptake inhibitor (SSRI) for oral administration for depression, bulimia, obsessive compulsive disorder, premenstrual dysphoric disorder (PMDD), including premenstrual syndrome (PMS), irritability, and dysphoria treatment. This work aims to study fluoxetine thermal behavior and decomposition, to establish a mechanism for its thermal decomposition. Kinetic and degradation studies should also be developed.Thermogravimetric measurements will be carried out in air and nitrogen atmosphere, allowing the determination of thermal stability of the drug and decomposition steps. Simultaneously, the gases evolved during heating of the sample will be taken through a transfer line, to a spectrometer. Thermogravimetry- spectroscopy in the infrared region(TG-FTIR) will be used in the identification of gas released during fluoxetine burning, permitting to propose a mechanism for its thermal decomposition. DSC analysis at temperatures below the decomposition events may show phase transition such as melting, polymorphic transformations, among others.
News published in Agência FAPESP Newsletter about the scholarship: